FT US Pharma and Biotech Summit - Postponed to 29 - 30 September 2020
The coronavirus pandemic has placed the pharma and biotech industries firmly in the spotlight. From R&D to the embrace of digital technologies and collaborations, no area of the business remains untouched. Meanwhile, innovations in burgeoning research areas to include cell and gene therapies will only increase as pharma reignites its drive for growth in a more challenging economic environment.
Through the lens of COVID-19 and the industry response the crisis, the 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the expansion of real-world evidence and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.